Fluoropyrimidines in Cancer Therapy by Youcef M. RustumFluoropyrimidines in Cancer Therapy by Youcef M. Rustum

Fluoropyrimidines in Cancer Therapy

EditorYoucef M. Rustum

Paperback | November 19, 2010

Pricing and Purchase Info


Earn 1,815 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.
Title:Fluoropyrimidines in Cancer TherapyFormat:PaperbackDimensions:337 pages, 10 × 7.01 × 0.01 inPublished:November 19, 2010Publisher:Humana PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:1617372749

ISBN - 13:9781617372742

Look for similar items by category:


Table of Contents

Relative Role of 5-Fluorouracil Activation and Inactivation Pathways on its Cytotoxic Effects: Preclinical and Clinical ModulationG. J. PetersDihydropyrimidine Dehydrogenase and Treatment by Fluoropyrimidines: Past and Future DirectionsGérard MilanoBiochemical Bases of the 5-Fluorouracil-Folinic Acid Interaction and of its Limitations: A Retrospective AnalysisRichard G. MoranMolecular Mechanisms Regulating the Expression of Thymidylate SynthaseJohn C. Schmitz, Ashwin Gollerkeri, Xiukun Lin, Jun Liu, and Edward ChuRegulation of Thymidylate Synthase Gene Expression and Drug Response: Posttranscriptional Regulation and Cell Population DensityBruce J. DolnickDeath Receptor Signaling in the Mechanism of 5-Fluorouracil ActionJanet A. HoughtonCircadian Rhythms in 5-Fluorouracil Pharmacology and Therapeutic ApplicationsFrancis LéviRelevance of Scheduling to the Efficacy of 5-Fluorouracil Alone and in Combination with Other AgentsAlberto F. Sobrero and Ornella BelvedereNoninvasive Studies of FluoropyrimidinesWalter Wolf, Cary A. Presant, and Victor WaluchComparative Antitumor Activity of 5-Fluorouracil (5-FU) Prodrugs in Preclinical Model Systems: Role of Leucovorin and Dihydropyrimidine Dehydrogenase InhibitorsShousong Cao, Gunnar Hapke, and Youcef M. RustumBimonthly 48-h Leucovorin and 5-Fluorouracil-Based Regimens in Advanced Colorectal CancerAimery de Gramont and Christophe LouvetReview on the Combination of Systemic and Locoregional Treatment for Colorectal Liver MetastasesRoberto Labianca, Gianfranco Pancera, Marinella Mastore, Marina Garassino, Giordano D. Beretta, Paola Poletti, and M. Adelaide PessiFluoropyrimidines in Advanced Colorectal Cancer: A Review of Six Consecutive Meta-AnalysesPascal Piedbois and Marc E. BuyseThe Mayo/NCCTG Experience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal CancerCharles Erlichman, Richard M. Goldberg, and Daniel J. SargentFluoropyrimidines for the Adjuvant Treatment of Colorectal Cancer: The NSABP ExperienceRoy E. Smith, Eleftherios P. Mamounas, and Norman WolmarkClinical Trials of UFT Leucovorin in Gastrointestinal MalignanciesPaulo M. Hoff and Everardo D. SaadThe Development of Oral UFT with and without LeucovorinGeert H. BlijhamUFT in Elderly Patients with Colorectal CancerAlbert Abad and José Luis ManzanoClinical Trials of the Eniluracil/5-Fluorouracil CombinationHedy L. Kindler and Richard L. SchilskyDiscovery and Preclinical Pharmacology of CapecitabineHideo IshitsukaCapecitabine, A Tumor-Targeting Oral Fluoropyrimidine: Molecular Rationale and Clinical ValidationDvorit SamidCapecitabine: A Rationally Developed Anticancer DrugDaniel R. BudmanPreclinical and Clinical Practice of S-1 in JapanTetsuhiko Shirasaka and Tetsuo TaguchiPreclinical and Clinical Practice of Low-Dose FP Therapy in Japan: Japanese Use of Low-Dose FP TherapyTetsuhiko Shirasaka, Akihito Tsuji, Susumu Yamamitsu, and Tetsuo Taguchi